Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimegepant Plus Glofitamab and CD19 CAR-T Cell Therapy in High-Risk Relapsed/Refractory Large B-Cell Lymphoma
NCT07613788Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- May 2026
- Primary completion
- Nov 2028
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rimegepant in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Ruijin Hospital. Primary endpoint: Complete Response Rate at 6 months. Planned start May 2026; status: not yet recruiting.
02
Drugs
rimegepant
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07613788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07613788.